The DOI matches its Crossref record; 266 of the 266 references it cites were found in a registry or an index.
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
Open accessAbstract
Triple-negative breast cancer (TNBC), characterized by the absence or low expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2), is the most aggressive subtype of breast cancer. TNBC accounts for about 15% of breast cancer cases in the U.S., and is known for high relapse rates and poor overall survival (OS). Chemo-resistant TNBC is a genetically diverse, highly heterogeneous, and rapidly evolving disease that challenges our ability to individualize treatment for incomplete responders and relapsed patients. Currently, the frontline standard chemotherapy, composed of anthracyclines, alkylating agents, and taxanes, is commonly used to treat high-risk and locally advanced TNBC. Several FDA-approved drugs that target programmed cell death protein-1 (Keytruda) and programmed death ligand-1 (Tecentriq), poly ADP-ribose polymerase (PARP), and/or antibody drug conjugates (Trodelvy) have shown promise in improving clinical outcomes for a subset of TNBC. These inhibitors that target key genetic mutations and specific molecular signaling pathways that drive malignant tumor growth have been used as single agents and/or in combination with standard chemotherapy regimens. Here, we review the current TNBC treatment options, unmet clinical needs, and actionable drug targets, including epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), androgen receptor (AR), estrogen receptor beta (ERβ), phosphoinositide-3 kinase (PI3K), mammalian target of rapamycin (mTOR), and protein kinase B (PKB or AKT) activation in TNBC. Supported by strong evidence in developmental, evolutionary, and cancer biology, we propose that the K-RAS/SIAH pathway activation is a major tumor driver, and SIAH is a new drug target, a therapy-responsive prognostic biomarker, and a major tumor vulnerability in TNBC. Since persistent K-RAS/SIAH/EGFR pathway activation endows TNBC tumor cells with chemo-resistance, aggressive dissemination, and early relapse, we hope to design an anti-SIAH-centered anti-K-RAS/EGFR targeted therapy as a novel therapeutic strategy to control and eradicate incurable TNBC in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–266 of 266
Adams, S., Dieras, V. C., Barrios, C. H., Winer, E. P., Schneeweiß, A., Iwata, H., Loi, S., Patel, S., Henschel, V., Chui, S. Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.003 · Cited by 94
Robson, M. E., Ruddy, K. J., Im, S., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Li, W., Tung, N., Armstrong, A. C., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.023 · Cited by 93
Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
Brockwell, N. K., Owen, K. L., Zanker, D. J., Spurling, A., Rautela, J., Duivenvoorden, H. M., Baschuk, N., Caramia, F., Loi, S., Darcy, P. K., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0150 · Cited by 92
Expression and clinical significance of MAPK and EGFR in triple‑negative breast cancer
Jiang, W., Wang, X., Zhang, C., Xue, L., & Yang, L. (2020) · Oncology Letters · doi:10.3892/ol.2020.11274 · Cited by 88
ERβ1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR
Thomas, C. G., Rajapaksa, G. K., Nikolos, F., Hao, R., Katchy, A., McCollum, C. W., Bondesson, M., Quinlan, P., Thompson, A. M., Krishnamurthy, S., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3358 · Cited by 87
Nahleh, Z. A., Barlow, W. E., Hayes, D. F., Schott, A. F., Gralow, J. R., Sikov, W. M., Perez, E. A., Chennuru, S., Mirshahidi, H., Corso, S. W., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3889-6 · Cited by 87
The Ras Signaling Pathway in Mammary Tumorigenesis and Metastasis
Malaney, S., & Daly, R. J. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009572700317 · Cited by 85
Paoletti, C., Li, Y., Muñiz, M. C., Kidwell, K., Aung, K., Thomas, D. G., Brown, M. E., Abramson, V. G., Irvin, W., Lin, N., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2781 · Cited by 83
Gass, P., Lux, M. P., Rauh, C., Hein, A., Bani, M. R., Fiessler, C., Hartmann, A., Häberle, L., Pretscher, J., Erber, R., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4925-1 · Cited by 83
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer
Martín, M., Rodríguez-Lescure, Á., Ruı́z, A., Alba, E., Calvo, L., Ruíz‐Borrego, M., Santaballa, A., Rodriguez, C. A., Crespo, C., Abad, M., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0663-z · Cited by 81
Nakajima, H., Ishikawa, Y., Furuya, M., Sano, T., Ohno, Y., Horiguchi, J., & Oyama, T. (2012) · Breast Cancer · doi:10.1007/s12282-012-0354-1 · Cited by 81
Schmidt, R. L., Park, C. H., Ahmed, A. U., Gundelach, J. H., Reed, N. R., Shen, C., Knudsen, B. E., & Tang, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4471 · Cited by 77
Self-citationEffect of Disrupting Seven-in-Absentia Homolog 2 Function on Lung Cancer Cell Growth
Ahmed, A. U., Schmidt, R. L., Park, C. H., Reed, N. R., Hesse, S. E., Thomas, C. F., Molina, J. R., Deschamps, C. C., Yang, P., Aubry, M. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn365 · Cited by 76
Self-citationTheriault, R. L., Litton, J. K., Mittendorf, E. A., Chen, H., Meric‐Bernstam, F., Chávez‐MacGregor, M., Morrow, P. K. H., Woodward, W. A., Şahin, A. A., Hortobágyi, G. N., et al. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.05.002 · Cited by 75
Lee, J., Kim, D.-M., & Lee, A.-W. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.270 · Cited by 75
Ricciardi, G. R. R., Adamo, B., Ieni, A., Licata, L., Cardia, R., Ferraro, G., Franchina, T., Tuccari, G., & Adamo, V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128368 · Cited by 73
Nagayama, A., Hayashida, T., Jinno, H., Takahashi, M., Seki, T., Matsumoto, A., Murata, T., Ashrafian, H., Athanasiou, T., Okabayashi, K., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju203 · Cited by 73
Reese, J. M., Suman, V. J., Subramaniam, M., Wu, X., Negron, V. C., Gingery, A., Pitel, K. S., Shah, S., Cunliffe, H. E., McCullough, A. E., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-749 · Cited by 71
Self-citationWright, K. L., Adams, J. R., Liu, J. C., Loch, A. J., Wong, R. G., Jo, C. E. B., Beck, L. A., Santhanam, D. R., Weiss, L. S., Mei, X., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2992 · Cited by 68
Landscape of Neoadjuvant Therapy for Breast Cancer
Haddad, T. C., & Goetz, M. P. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4405-7 · Cited by 68
Self-citationAsano, Y., Kashiwagi, S., Goto, W., Takada, K., Takahashi, K., Hatano, T., Noda, S., Takashima, T., Onoda, N., Tomita, S., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3927-8 · Cited by 68
Incidence and survival among young women with stage I-III breast cancer: Seer 2000-2015
Thomas, A., Rhoads, A., Pinkerton, E., Schroeder, M. C., Conway, K. M., Hundley, W. G., McNally, L. R., Oleson, J., Lynch, C. F., & Romitti, P. A. (2019) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz040 · Cited by 68
Shanle, E. K., Zhao, Z., Hawse, J. R., Wisinski, K. B., Keleş, S., Yuan, M., & Xu, W. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1164 · Cited by 67
Prado-Vázquez, G., Gámez‐Pozo, A., Trilla‐Fuertes, L., Arevalillo, J. M., Zapater‐Moros, A., Ferrer-Gómez, M., Díaz‐Almirón, M., López‐Vacas, R., Navarro, H., Maín, P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-38364-y · Cited by 67
Insights into the Role of Estrogen Receptor β in Triple-Negative Breast Cancer
Sellitto, A., D’Agostino, Y., Alexandrova, E., Lamberti, J., Pecoraro, G., Memoli, D., Rocco, D., Coviello, E., Giurato, G., Nassa, G., et al. (2020) · Cancers · doi:10.3390/cancers12061477 · Cited by 67
Schüler‐Toprak, S., Häring, J., Inwald, E. C., Moehle, C., Ortmann, O., & Treeck, O. (2016) · BMC Cancer · doi:10.1186/s12885-016-2973-y · Cited by 65
Reese, J. M., Bruinsma, E. S., Nelson, A. W., Chernukhin, I. V., Carroll, J. S., Li, Y., Subramaniam, M., Suman, V. J., Negron, V. C., Monroe, D. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807751115 · Cited by 64
Self-citationHomologous recombination DNA repair defects in PALB2-associated breast cancers
Li, A., Geyer, F. C., Blecua, P., Lee, J. Y., Selenica, P., Brown, D. N., Pareja, F. G., Lee, S., Kumar, R., Rivera, B., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0115-9 · Cited by 64
Molecular Trajectory of BRCA1 and BRCA2 Mutations
Hatano, Y., Tamada, M., Matsuo, M., & Hara, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00361 · Cited by 64
Estrogen receptor-beta is a potential target for triple negative breast cancer treatment
Austin, D., Hamilton, N. M., Elshimali, Y., Pietras, R. J., Wu, Y., & Vadgama, J. V. (2018) · Oncotarget · doi:10.18632/oncotarget.26089 · Cited by 62
LeVasseur, N., Sun, J., Gondara, L., Diocee, R. M., Speers, C. H., Lohrisch, C. A., & Chia, S. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03083-y · Cited by 60
New targets in triple-negative breast cancer
Copeland, R., & KANAAN, Y. M. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00415-4 · Cited by 59
Biomarkers of residual disease after neoadjuvant therapy for breast cancer
Penault-Llorca, F. M., & Radosevic‐Robin, N. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.1 · Cited by 57
Chan, J. J., Tan, T. J., & Dent, R. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919880429 · Cited by 56
Swain, S. M., Tang, G., Brauer, H. A., Goerlitz, D. S., Lucas, P. C., Robidoux, A., Harris, B. T., Bandos, H., Ren, Y., Geyer, C. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0152 · Cited by 56
Wu, K., Yang, Q.-Z., Liu, Y., Wu, A., & Yang, Z. (2014) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-12-95 · Cited by 55
Schwartzberg, L. S., Yardley, D. A., ELIAS, A. D., Patel, M. R., LoRusso, P. M., Burris, H. A., Gucalp, A., Peterson, A., Blaney, M. E., Steinberg, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2339 · Cited by 55
I-SPY 2 — Toward More Rapid Progress in Breast Cancer Treatment
Carey, L., & Winer, E. P. (2016) · New England Journal of Medicine · doi:10.1056/nejme1603691 · Cited by 54
Dieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv241 · Cited by 48
Asano, Y., Kashiwagi, S., Goto, W., Takada, K., Takahashi, K., Morisaki, T., Fujita, H., Takashima, T., Tomita, S., Ohsawa, M., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1458-y · Cited by 48
Parinyanitikul, N., Lei, X. J., Chávez‐MacGregor, M., Liu, S., Mittendorf, E. A., Litton, J. K., Woodward, W. A., Zhang, A. (., Hortobágyi, G. N., Valero, V., et al. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.09.006 · Cited by 47
ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
Reese, J. M., Bruinsma, E. S., Monroe, D. G., Negron, V. C., Suman, V. J., Ingle, J. N., Goetz, M. P., & Hawse, J. R. (2017) · Oncotarget · doi:10.18632/oncotarget.21787 · Cited by 43
Self-citationEllsworth, D. L., Turner, C., & Ellsworth, R. E. (2019) · Journal of Oncology · doi:10.1155/2019/4382606 · Cited by 42
New targets for triple-negative breast cancer.
Herold, C. I., & Anders, C. K. (2013) · PubMed · Cited by 41
Swain, S. M., Tang, G., Lucas, P. C., Robidoux, A., Goerlitz, D. S., Harris, B. T., Bandos, H., Geyer, C. E., Rastogi, P., Mamounas, E. P., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05398-3 · Cited by 41
Pinard, C., Debled, M., Rejeb, H. B., Velasco, V., de Lara, C. T., Hoppe, S., Richard, É., Brouste, V., Bonnefoi, H. R., & MacGrogan, G. M. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05437-z · Cited by 40
Translating the role of PARP inhibitors in triple-negative breast cancer
Beniey, M., Haque, T., & Hassan, S. N. (2019) · Oncoscience · doi:10.18632/oncoscience.474 · Cited by 40
Li, Y., Zhou, Y., Mao, F., Lin, Y., Zhang, X., Shen, S., & Sun, Q. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05513-4 · Cited by 37
Pembrolizumab for Early Triple-Negative Breast Cancer. Reply.
Schmid, P., Dent, R. A., & O’Shaughnessy, J. (2020) · PubMed · doi:10.1056/nejmc2006684 · Cited by 36
Outcomes of Delays in Time to Treatment in Triple Negative Breast Cancer
Eastman, A. L., Tammaro, Y., Moldrem, A. W., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2835-z · Cited by 35
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation
Pelizzari, G., Gerratana, L., Basile, D., Fanotto, V., Bartoletti, M., Liguori, A., Fontanella, C., Spazzapan, S., & Puglisi, F. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.014 · Cited by 34
Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer
Savard, M.-F., Khan, O. F., Hunt, K. K., & Verma, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237419 · Cited by 31
van Reesema, L. L. S., Zheleva, V. P., Winston, J. S., Jansen, R. J., O’Connor, C. F., Isbell, A. J., Bian, M., Qin, R., Bassett, P. T., Hinson, V. J., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.014 · Cited by 28
Self-citationHe, J., Tsang, J. Y., Xu, X., Li, J., Li, M., Chao, X., Xu, Y., Luo, R., Tse, G. M.-K., & Sun, P. (2020) · BMC Cancer · doi:10.1186/s12885-019-6494-3 · Cited by 28
Kennedy, W. R., Tricarico, C. J., Gabani, P., Weiner, A. A., Altman, M. B., Ochoa, L. L., Thomas, M. A., Margenthaler, J. A., Sanati, S., Peterson, L. L., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7366 · Cited by 28
Gagan, G., Lee, D. C., Guye, M. L., Sciver, R. E. V., Lee, P., Lafever, A., Anthony, P., Tang-Tan Angela, M., Winston, J. S., Şamli, B., et al. (2020) · Annals of Breast Cancer and Therapy · doi:10.36959/739/525 · Cited by 25
Self-citationIncreased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma
Behling, K. C., Tang, A., Freydin, B., Chervoneva, I., Kadakia, S., Schwartz, G. F., Rui, H., & Witkiewicz, A. K. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1254-8 · Cited by 23
Self-citationTumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest?
Parker, J. S., & Perou, C. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.011 · Cited by 22
Tobin, N. P., Lundberg, A., Lindström, L. S., Harrell, J. C., Foukakis, T., Carlsson, L. M. S., Einbeigi, Z., Linderholm, B. K., Loman, N., Malmberg, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2301 · Cited by 21
Sciver, R. E. V., Lee, M., Lee, C., Lafever, A., Svyatova, E. A., Kanda, K., Collier, A. L., van Reesema, L. L. S., Tang-Tan, A. M., Zheleva, V. P., et al. (2018) · Cancers · doi:10.3390/cancers10050142 · Cited by 21
Self-citationHoyer, J., Vasileiou, G., Uebe, S., Wunderle, M., Kraus, C. S., Fasching, P. A., Thiel, C. T., Hartmann, A., Beckmann, M. W., Lux, M. P., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4821-8 · Cited by 21
Sciver, R. E. V., Njogu, M. M., Isbell, A. J., Odanga, J. J., Bian, M., Svyatova, E., van Reesema, L. L. S., Zheleva, V. P., Eisner, J., Bruflat, J. K., et al. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00012-6 · Cited by 11
Self-citationChemotherapy as a TONIC to invigorate PD-1 inhibition in TNBC
Killock, D. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0232-2 · Cited by 9
Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review)
McCubrey, J. A., Bonati, A., Libra, M., Stivala, F., Martelli, A. M., Franklin, R. A., Navolanic, P. M., & Steelman, L. S. (2008) · Molecular Medicine Reports · doi:10.3892/mmr.1.2.139 · Cited by 8
Setting dictates efficacy of pembrolizumab in TNBC
Sidaway, P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0157-1 · Cited by 7
Building momentum for subsets of patients with advanced triple-negative breast cancer
Woodward, W. A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30737-5 · Cited by 3
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Gong, J., Cheng, D., Liu, C., Wu, S., Sun, N., Zhao, L., Li, J., Xing, Y., & Zhao, J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202404184 · Cited by 53
Metadata
- Authors
- Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., Samli, B., Jansen, R. J., Petricoin, E. F., Goetz, M. P., Bear, H. D., & Tang, A. H.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-08-24
- Volume
- 12
- Issue
- 9
- Pages
- 2392
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3081189407
- Cited by
- 331
- References
- 266
- FWCI
- 13.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.